NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis $2.25 -0.01 (-0.27%) As of 09:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Akebia Therapeutics Stock (NASDAQ:AKBA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Akebia Therapeutics alerts:Sign Up Key Stats Today's Range$2.22▼$2.2250-Day Range$1.69▼$2.3952-Week Range$0.80▼$2.48Volume101,408 shsAverage Volume2.61 million shsMarket Capitalization$491.78 millionP/E RatioN/ADividend YieldN/APrice Target$6.75Consensus RatingBuy Company OverviewAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More… Remove Ads Akebia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreAKBA MarketRank™: Akebia Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 247th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Akebia Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -9.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -9.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Akebia Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.11% of the float of Akebia Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Akebia Therapeutics has recently decreased by 0.67%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-1.35 Percentage of Shares Shorted7.11% of the float of Akebia Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Akebia Therapeutics has recently decreased by 0.67%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News Sentiment0.23 News SentimentAkebia Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Akebia Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 26 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows6 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $589,216.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 33.92% of the stock of Akebia Therapeutics is held by institutions.Read more about Akebia Therapeutics' insider trading history. Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Stock News HeadlinesAkebia Therapeutics' (AKBA) "Buy" Rating Reiterated at HC WainwrightMarch 17 at 2:27 AM | americanbankingnews.comUS$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These ResultsMarch 16 at 5:03 PM | finance.yahoo.comLying in hospital… staring at the light"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.March 17, 2025 | Porter & Company (Ad)Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call TranscriptMarch 15 at 6:33 PM | seekingalpha.comAkebia price target raised to $6 from $4 at Piper SandlerMarch 14 at 10:25 AM | markets.businessinsider.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2024 Earnings Call TranscriptMarch 14 at 9:17 AM | insidermonkey.comQ4 2024 Akebia Therapeutics Inc Earnings CallMarch 14 at 5:24 AM | uk.finance.yahoo.comAkebia reports Q4 EPS (10c) vs 0c last yearMarch 13, 2025 | markets.businessinsider.comSee More Headlines AKBA Stock Analysis - Frequently Asked Questions How have AKBA shares performed this year? Akebia Therapeutics' stock was trading at $1.90 at the beginning of 2025. Since then, AKBA shares have increased by 18.9% and is now trading at $2.26. View the best growth stocks for 2025 here. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its quarterly earnings data on Thursday, March, 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.05. The biopharmaceutical company had revenue of $46.50 million for the quarter, compared to analysts' expectations of $37.36 million. Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' top institutional investors include Vanguard Group Inc. (4.99%), Geode Capital Management LLC (2.20%), Renaissance Technologies LLC (1.75%) and Northern Trust Corp (0.77%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, David A Spellman, Nicholas Grund and Richard C Malabre. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and Exxon Mobil (XOM). Company Calendar Last Earnings3/13/2025Today3/17/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKBA CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees430Year FoundedN/APrice Target and Rating Average Stock Price Target$6.75 High Stock Price Target$7.50 Low Stock Price Target$6.00 Potential Upside/Downside+198.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,920,000.00 Net Margins-27.07% Pretax Margin-27.08% Return on EquityN/A Return on Assets-20.57% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio1.21 Sales & Book Value Annual Sales$169.88 million Price / Sales2.90 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-14.13Miscellaneous Outstanding Shares218,181,000Free Float209,236,000Market Cap$493.09 million OptionableOptionable Beta0.94 Social Links 7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:AKBA) was last updated on 3/17/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.